Adicet Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Adicet Bio wird ein Gewinn- und Umsatzwachstum von 5.5% bzw. 65.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 8.1% pro Jahr wachsen soll.

Wichtige Informationen

16.8%

Wachstumsrate der Gewinne

21.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	56.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Dec 28

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Dec 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ACET - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	34	-106	-96	-123	7
12/31/2025	3	-125	-90	-111	9
12/31/2024	2	-119	-80	-88	9
3/31/2024	N/A	-140	-95	-92	N/A
12/31/2023	N/A	-143	-98	-94	N/A
9/30/2023	N/A	-143	-100	-89	N/A
6/30/2023	N/A	-115	-98	-83	N/A
3/31/2023	N/A	-105	-89	-73	N/A
12/31/2022	25	-70	-62	-45	N/A
9/30/2022	30	-56	-53	-39	N/A
6/30/2022	34	-48	-49	-34	N/A
3/31/2022	39	-36	-47	-32	N/A
12/31/2021	10	-62	-64	-51	N/A
9/30/2021	10	-55	-61	-51	N/A
6/30/2021	9	-56	-52	-49	N/A
3/31/2021	12	-54	-50	-48	N/A
12/31/2020	18	-37	-43	-42	N/A
9/30/2020	14	-34	-37	-35	N/A
6/30/2020	4	-34	-36	-35	N/A
3/31/2020	0	-28	-30	-29	N/A
12/31/2019	1	-28	-29	-28	N/A
12/31/2018	8	-9	-19	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACET wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACET wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACET wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACETDie Einnahmen des Unternehmens (65.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ACETDie Einnahmen des Unternehmens (65.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ACET in 3 Jahren voraussichtlich hoch sein wird

Adicet Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 18% to US$12.80

Price target decreased by 15% to US$18.29

Price target decreased by 14% to US$23.29

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Consensus revenue estimates increase by 180%, EPS downgraded

Recent updates

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Adicet Bio: A First Take

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Consensus revenue estimates increase by 42%

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

High number of new and inexperienced directors

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Chief Medical Officer & Senior VP notifies of intention to sell stock

Consensus forecasts updated

Consensus revenue estimates fall by 31%

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Founder & Independent Director notifies of intention to sell stock

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Founder & Independent Director notifies of intention to sell stock

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

CEO, President & Director notifies of intention to sell stock